These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 17301297

  • 21. The treatment of Kawasaki syndrome with intravenous gamma globulin.
    Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP.
    N Engl J Med; 1986 Aug 07; 315(6):341-7. PubMed ID: 2426590
    [Abstract] [Full Text] [Related]

  • 22. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease.
    Miura M, Ohki H, Yoshiba S, Ueda H, Sugaya A, Satoh M, Yamagishi H.
    Arch Dis Child; 2005 Oct 07; 90(10):1096-7. PubMed ID: 16177169
    [No Abstract] [Full Text] [Related]

  • 23. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H.
    Pediatr Int; 1999 Feb 07; 41(1):1-7. PubMed ID: 10200128
    [Abstract] [Full Text] [Related]

  • 24. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Ogata S, Bando Y, Kimura S, Ando H, Nakahata Y, Ogihara Y, Kaneko T, Minoura K, Kaida M, Yokota Y, Furukawa S, Ishii M.
    J Cardiol; 2009 Feb 07; 53(1):15-9. PubMed ID: 19167633
    [Abstract] [Full Text] [Related]

  • 25. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S, Dong Y, Yin Y, Krucoff MW.
    Heart; 2013 Jan 07; 99(2):76-82. PubMed ID: 22869678
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
    Kuo HC, Guo MM, Lo MH, Hsieh KS, Huang YH.
    BMC Pediatr; 2018 Jun 22; 18(1):200. PubMed ID: 29933749
    [Abstract] [Full Text] [Related]

  • 27. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
    Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW.
    JAMA Pediatr; 2016 Dec 01; 170(12):1156-1163. PubMed ID: 27749951
    [Abstract] [Full Text] [Related]

  • 28. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T, Ogata S, Ogihara Y, Fujimoto M, Kitagawa A, Takanashi M, Ishii M.
    J Pediatr; 2017 Dec 01; 191():140-144. PubMed ID: 29173297
    [Abstract] [Full Text] [Related]

  • 29. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 30. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 27; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 31. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
    Nihon Rinsho; 2008 Feb 27; 66(2):338-42. PubMed ID: 18265457
    [Abstract] [Full Text] [Related]

  • 32. [Steroid pulse therapy].
    Miura M.
    Nihon Rinsho; 2014 Sep 27; 72(9):1631-5. PubMed ID: 25518414
    [Abstract] [Full Text] [Related]

  • 33. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
    Chiang MH, Liu HE, Wang JL.
    Arch Dis Child; 2021 Jul 27; 106(7):662-668. PubMed ID: 33172886
    [Abstract] [Full Text] [Related]

  • 34. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
    Pilania RK, Jindal AK, Johnson N, Prithvi A, Vignesh P, Suri D, Rawat A, Gupta A, Singh S.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3413-3419. PubMed ID: 33221920
    [Abstract] [Full Text] [Related]

  • 35. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
    J Pediatr; 2006 Sep 01; 149(3):336-341. PubMed ID: 16939743
    [Abstract] [Full Text] [Related]

  • 36. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
    Yang TJ, Lin MT, Lu CY, Chen JM, Lee PI, Huang LM, Wu MH, Chang LY.
    J Microbiol Immunol Infect; 2018 Jun 01; 51(3):321-331. PubMed ID: 28927685
    [Abstract] [Full Text] [Related]

  • 37. The use of corticosteroid therapy in refractory Kawasaki patients.
    Al-Mayouf SM.
    Clin Rheumatol; 2004 Feb 01; 23(1):11-3. PubMed ID: 14749974
    [Abstract] [Full Text] [Related]

  • 38. Response of refractory Kawasaki disease to intravenous methylprednisolone.
    Shah I, Prabhu SS.
    Ann Trop Paediatr; 2009 Mar 01; 29(1):51-3. PubMed ID: 19222935
    [Abstract] [Full Text] [Related]

  • 39. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ, Jung JW.
    Yonsei Med J; 2014 Sep 01; 55(5):1260-6. PubMed ID: 25048483
    [Abstract] [Full Text] [Related]

  • 40. Role of glucocorticoids in Kawasaki disease.
    Miura M.
    Int J Rheum Dis; 2018 Jan 01; 21(1):70-75. PubMed ID: 29105310
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.